Genomics investments start to pay off

12/18/2012 | Xconomy

Investments in whole genome sequencing and analysis are starting to pay off, with new drugs, diagnostics and disease management strategies, Luke Timmerman writes. Two companies, Adaptive Biotechnologies and Sequenta, are pioneering new approaches to disease diagnosis and management through sequencing that would have been cost-prohibitive several years ago. Studies are under way to determine whether genomics technologies will lower health care costs and improve outcomes, but the personalized medicine payoff is imminent, Timmerman writes.

View Full Article in:

Xconomy

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT